MeVis Medical Solutions AGFRA:M3V 66 ROA % is 5.07% as of Mar. 2026, which is 70% below its 10-year median of 16.67. GuruFocus rates FRA:M3V with a GF Score™ of 66/100 and a GF Value™ of €22.52. The stock has 4 warning signs investors should review. Among 686 Healthcare Providers & Services companies, MeVis Medical Solutions AG ranks better than 70.85% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. MeVis Medical Solutions AG's annualizedNet Income for the quarter that ended in Mar. 2026 was €1.24 Mil.
MeVis Medical Solutions AG's average Total Assets over the quarter that ended in Mar. 2026 was €24.52 Mil. Therefore, MeVis Medical Solutions AG's annualized ROA % for the quarter that ended in Mar. 2026 was 5.07%.
The historical rank and industry rank for MeVis Medical Solutions AG's ROA % or its related term are showing as below:
FRA:M3V'
s ROA % Range Over the Past 10 Years
Min: 5.72 Med: 16.67 Max: 33.68
Current: 5.72
During the past 13 years, MeVis Medical Solutions AG's highest ROA % was 33.68%. The lowest was 5.72%. And the median was 16.67%.
FRA:M3V's ROA % is ranked better than 70.85% of 686
companies
in the Healthcare Providers & Services industry
Industry Median: 1.75
vs FRA:M3V: 5.72
MeVis Medical Solutions AG (FRA:M3V) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Mar. 2026) net income data. The Revenue data used here is two times the semi-annual (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, MeVis Medical Solutions AG's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MeVis Medical Solutions AG ROA % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, MeVis Medical Solutions AG's ROA % distribution charts can be found below:
* The bar in red indicates where MeVis Medical Solutions AG's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
MeVis Medical Solutions AG (FRA:M3V) has a ROA % of 5.07% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on MeVis Medical Solutions AG and its competitors. This is 70% below median its historical median of 16.67. Over the past decade, MeVis Medical Solutions AG's ROA % has ranged from 5.72 to 33.68. According to the industry distribution chart, MeVis Medical Solutions AG ranks #200 out of 686 companies in the Healthcare Providers & Services industry, placing it in the top 29.2%.
Is MeVis Medical Solutions AG's ROA % too high?
MeVis Medical Solutions AG's current ROA % of 5.07% is 70% below median its 10-year median of 16.67. Over the past 10 years, this metric has ranged from a low of 5.72 to a high of 33.68. The Healthcare Providers & Services industry median ROA % is 1.75. MeVis Medical Solutions AG's value of 5.07% is 189.7% above this industry median. Based on the distribution chart, MeVis Medical Solutions AG ranks #200 out of 686 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, MeVis Medical Solutions AG has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does MeVis Medical Solutions AG's ROA % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, MeVis Medical Solutions AG ranks #200 out of 686 companies for ROA %. This puts MeVis Medical Solutions AG in the upper half of its industry. The industry median ROA % is 1.75. MeVis Medical Solutions AG's value of 5.07% is 189.7% above this benchmark. Historically, MeVis Medical Solutions AG's own ROA % has ranged from 5.72 to 33.68 over the past decade. While the company's 10-year median is 16.67 vs. the industry median of 1.75, MeVis Medical Solutions AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Healthcare Providers & Services company?
The median ROA % among Healthcare Providers & Services companies is 1.75, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MeVis Medical Solutions AG's current ROA % of 5.07% is 189.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on MeVis Medical Solutions AG and its competitors. For the Healthcare Providers & Services industry, the median ROA % is 1.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MeVis Medical Solutions AG's current ROA % is 5.07%, which is 70% below median its own 10-year median of 16.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MeVis Medical Solutions AG stock overvalued right now?
MeVis Medical Solutions AG (FRA:M3V) has a current ROA % of 5.07%. The stock's GF Value™ is €22.52, compared to a current price of €23.20 — trading 3% above its estimated fair value. The current ROA % is 5.07%, which is 70% below median its 10-year median of 16.67 and 189.7% above the Healthcare Providers & Services industry median of 1.75. MeVis Medical Solutions AG's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For MeVis Medical Solutions AG (FRA:M3V), the current ROA % is 5.07% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MeVis Medical Solutions AG (FRA:M3V) Overvalued in 2026?
Based on GuruFocus' analysis, MeVis Medical Solutions AG stock appears to be overvalued.
The current stock price of €23.20 is trading 3% above its estimated GF Value™ of €22.52.
Key valuation signals for FRA:M3V:
ROA %: 5.07% (70% below median its 10-year median of 16.67)
GF Value™: €22.52 vs. price of €23.20 (3% above fair value)
Industry Position: 189.7% above the Healthcare Providers & Services median (#200 of 686)
No single metric tells the full story. See the FRA:M3V stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MeVis Medical Solutions AG is a provider of medical software products. The company markets its products to equipment manufacturer of medical devices and providers of medical information technology platforms. Its segment includes Digital mammography and Other diagnostics. The Digital mammography segment develops and markets software products which assist in breast diagnostic imaging and intervention. Its Other diagnostics segment consists of digital radiology products. In addition, it also provides the general analysis of radiology images. The company's geographical area of operations includes the United States of America and Europe.
66GF Score
Get the complete analysis for FRA:M3V
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:M3V has been successfully added to your 
